The effect of peroxisome proliferator activator receptor gamma agonist pre-treatment on pegylated interferon-alpha2a and ribavirin efficacy in hepatitis C patients, previously resistant to treatment with pegylated interferon and ribavirin - a randomized-controlled trial.

Trial Profile

The effect of peroxisome proliferator activator receptor gamma agonist pre-treatment on pegylated interferon-alpha2a and ribavirin efficacy in hepatitis C patients, previously resistant to treatment with pegylated interferon and ribavirin - a randomized-controlled trial.

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 25 Aug 2011

At a glance

  • Drugs Pioglitazone (Primary) ; Peginterferon alfa-2a; Ribavirin
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Acronyms HEPAR
  • Most Recent Events

    • 25 Aug 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top